This thesis describes the clinical investigation of a novel treatment strategy for type 2 diabetes mellitus (t2dm) using an antisense oligonucleotide(aon)to inhibit the sglt2 receptor. Furthermore... Show moreThis thesis describes the clinical investigation of a novel treatment strategy for type 2 diabetes mellitus (t2dm) using an antisense oligonucleotide(aon)to inhibit the sglt2 receptor. Furthermore it describes skin effects of oligonucleotides Show less
This thesis addresses various aspects regarding the treatment of patients with early, active rheumatoid arthritis. The main conclusion of this thesis is that patients with RA benefit from... Show moreThis thesis addresses various aspects regarding the treatment of patients with early, active rheumatoid arthritis. The main conclusion of this thesis is that patients with RA benefit from combination therapy on the short-term, and the treat-to-target approach determines the success of the long-term outcomes. Following this strategy, high percentages of low disease activity and remission are achieved, and even drug-free remission has shown to be realistic outcome. As a result, functional ability remains stable over time (after improvement during the first year after initiating treatment), radiographic progression is limited in most patients and excess mortality was not observed. Show less
This report introduces a framework for comparing radiotherapy treatment planning in multicentric in silico clinical trials. Quality assurance, data incompatibility, transfer and storage issues, and... Show moreThis report introduces a framework for comparing radiotherapy treatment planning in multicentric in silico clinical trials. Quality assurance, data incompatibility, transfer and storage issues, and uniform analysis of results are discussed. The solutions that are given provide a useful guide for the set-up of future multicentric planning studies or public repositories of high quality data. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 97 (2010) 567-571 Show less
